[Clinical evaluation of a new synthetic respiratory analeptic: 3,3-diphenyl-1-ethyl-4(alpha-morpholinoethyl)-pyrrolidone chlorhydrate].
D000759:Adjuvants, Anesthesia / Q000494:pharmacology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D002648:Child; D004315:Doxapram / Q000494:pharmacology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology*; D011674:Pulse / Q000187:drug effects*; D011760:Pyrrolidinones / Q000494:pharmacology*; D012119:Respiration / Q000187:drug effects*; D012126:Respiratory Dead Space
D000759:Adjuvants, Anesthesia; D000697:Central Nervous System Stimulants; D009025:Morpholines; D011760:Pyrrolidinones; D004315:Doxapram
Valutazione clinica di un nuovo analettico respiratorio di sintesi: il 3,3-difenil-1-etil-4-(alpha-morfolinoetil)-pirrolidone cloridrato.